October 27, 2026
How Can Metabolomics Detect Drug Toxicity Early? How much does our environment influence our health—and what could that mean for precision medicine? How can researchers identify drug toxicity before it becomes a clinical problem? Metabolomics may offer a way to detect potential safety risks earlier in drug development. In this episode of ChatGJP, Panome Bio […]
October 22, 2026
Can Metabolomics Explain Differences in Drug Response? How much does our environment influence our health—and what could that mean for precision medicine? Why does a drug work well for some patients but have little effect on others? Differences in underlying disease biology may hold important clues. In this episode of ChatGJP, Panome Bio CSO Gary […]
October 19, 2026
What Industries Benefit from Exposomics Analysis? How much does our environment influence our health—and what could that mean for precision medicine? Which industries can benefit from exposomics analysis? The answer extends beyond healthcare. In this episode of ChatGJP, Panome Bio CSO Gary J. Patti explains how exposomics can provide valuable insights for drug development, precision […]
October 1, 2026
Why Has Genomics Not Solved Most Chronic Diseases? Why hasn’t genomics solved most chronic diseases? In this episode of ChatGJP, Panome Bio CSO Gary J. Patti explains why genomics has provided valuable insights into health and disease, but cannot capture every factor that influences an individual’s health. While genomics has been applied at enormous population […]
September 29, 2026
How Is Multi-Omics Changing Chronic Disease Diagnosis? How is multi-omics changing the way researchers define and diagnose chronic disease? In this episode of ChatGJP, Panome Bio CSO Gary J. Patti explains how combining molecular data can provide greater resolution into the biological differences between patients and disease states. Chronic diseases can exist along a spectrum, […]
July 22, 2026
How Exposomics Can Improve Clinical Trials and Precision Medicine Why do promising drugs fail in Phase III clinical trials? Why do patients respond differently to the same therapy across countries? And if genetics only explains part of disease risk, what information is missing? In this episode of ChatGJP, Tom Cohen, President of Panome Bio, discusses […]
July 16, 2026
How are exposure patterns linked to biological pathways? Environmental chemical exposures can significantly influence drug metabolism, therapeutic response, and disease biology—but they are often overlooked in biomedical research and clinical development. In this episode of ChatGJP, Ethan Stancliffe, Senior Director of R&D, explains how environmental chemicals interact with cytochrome P450 enzymes, why chemical exposure burden […]
March 27, 2024
ChatGJP “Metabolomics for drug development” Welcome to Panome Bio’s ChatGJP series with CSO Gary J. Patti, Ph.D. In this session, we ask Dr. Patti, “How is metabolomics being employed in drug development and pharmacology to enhance the efficiency of drug discovery and understand drug metabolism?”